As of 2025-05-16, the Intrinsic Value of NLS Pharmaceutics AG (NLSP) is -13.34 USD. This NLSP valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.61 USD, the upside of NLS Pharmaceutics AG is -928.40%.
Based on its market price of 1.61 USD and our intrinsic valuation, NLS Pharmaceutics AG (NLSP) is overvalued by 928.40%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -13.34 - -13.34 | -13.34 | -928.40% |
| P/E | (51.59) - (52.50) | (54.08) | -3459.2% |
| DDM - Stable | (20.67) - (201.30) | (110.99) | -6993.5% |
| DDM - Multi | (34.36) - (279.47) | (62.81) | -4001.3% |
| Market Cap (mil) | 3.98 |
| Beta | 0.02 |
| Outstanding shares (mil) | 2.47 |
| Enterprise Value (mil) | 5.14 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.11% |
| Cost of Debt | 5.00% |
| WACC | 7.55% |